Skip to content
Independent investment research since 1991 Linden, New Jersey · 908-975-0250
Lark Research High Quality Independent Investment Research

Risk/Reward archive

GAAP vs. Non-GAAP

April 22, 2016Health Care · MRK

An Update on Merck (MRK)

Product Pipeline Successes. Merck has enjoyed a couple of notable successes in its product pipeline over the past year. The first and most important is Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) immunotherapy treatment for cancer. Keytruda…

Continue reading →